nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—ABCG2—Dactinomycin—ocular cancer	0.155	0.492	CbGbCtD
Nilotinib—ABCG2—Carboplatin—ocular cancer	0.104	0.331	CbGbCtD
Nilotinib—ABCB1—Dactinomycin—ocular cancer	0.0557	0.177	CbGbCtD
Nilotinib—CA6—ear—ocular cancer	0.0125	0.085	CbGeAlD
Nilotinib—CA3—ear—ocular cancer	0.0118	0.0805	CbGeAlD
Nilotinib—EPHB2—retina—ocular cancer	0.00567	0.0386	CbGeAlD
Nilotinib—EPHA8—eye—ocular cancer	0.00549	0.0373	CbGeAlD
Nilotinib—CDC42BPB—eye—ocular cancer	0.00506	0.0344	CbGeAlD
Nilotinib—CDC42BPB—retina—ocular cancer	0.00501	0.0341	CbGeAlD
Nilotinib—EPHA3—eye—ocular cancer	0.00479	0.0326	CbGeAlD
Nilotinib—EPHA3—retina—ocular cancer	0.00475	0.0323	CbGeAlD
Nilotinib—MAPK8—eye—ocular cancer	0.00457	0.0311	CbGeAlD
Nilotinib—MAPK8—retina—ocular cancer	0.00453	0.0308	CbGeAlD
Nilotinib—FRK—lymphoid tissue—ocular cancer	0.00423	0.0288	CbGeAlD
Nilotinib—MAPK8—epithelium—ocular cancer	0.00418	0.0285	CbGeAlD
Nilotinib—MAP4K1—retina—ocular cancer	0.00412	0.028	CbGeAlD
Nilotinib—BLK—lymphoid tissue—ocular cancer	0.00408	0.0277	CbGeAlD
Nilotinib—EPHB2—lymphoid tissue—ocular cancer	0.00403	0.0274	CbGeAlD
Nilotinib—TIE1—epithelium—ocular cancer	0.00363	0.0247	CbGeAlD
Nilotinib—MAPK8—lymphoid tissue—ocular cancer	0.00322	0.0219	CbGeAlD
Nilotinib—LYN—lymphoid tissue—ocular cancer	0.00297	0.0202	CbGeAlD
Nilotinib—MAP4K1—lymphoid tissue—ocular cancer	0.00293	0.0199	CbGeAlD
Nilotinib—MAPK14—epithelium—ocular cancer	0.00266	0.0181	CbGeAlD
Nilotinib—EPHB4—epithelium—ocular cancer	0.00252	0.0171	CbGeAlD
Nilotinib—EPHA2—epithelium—ocular cancer	0.00247	0.0168	CbGeAlD
Nilotinib—HCK—lymphoid tissue—ocular cancer	0.00244	0.0166	CbGeAlD
Nilotinib—TEK—epithelium—ocular cancer	0.00241	0.0164	CbGeAlD
Nilotinib—CA12—eye—ocular cancer	0.0022	0.015	CbGeAlD
Nilotinib—CSF1R—eye—ocular cancer	0.0021	0.0143	CbGeAlD
Nilotinib—MAPK14—lymphoid tissue—ocular cancer	0.00205	0.0139	CbGeAlD
Nilotinib—FGR—lymphoid tissue—ocular cancer	0.00204	0.0139	CbGeAlD
Nilotinib—EPHA2—lymphoid tissue—ocular cancer	0.0019	0.013	CbGeAlD
Nilotinib—PDGFRB—eye—ocular cancer	0.00186	0.0127	CbGeAlD
Nilotinib—TEK—lymphoid tissue—ocular cancer	0.00186	0.0126	CbGeAlD
Nilotinib—KIT—epithelium—ocular cancer	0.00175	0.0119	CbGeAlD
Nilotinib—CA1—eye—ocular cancer	0.00175	0.0119	CbGeAlD
Nilotinib—PDGFRB—epithelium—ocular cancer	0.00171	0.0116	CbGeAlD
Nilotinib—PDGFRA—lymphoid tissue—ocular cancer	0.00168	0.0114	CbGeAlD
Nilotinib—ABL1—eye—ocular cancer	0.00166	0.0113	CbGeAlD
Nilotinib—ABL1—retina—ocular cancer	0.00165	0.0112	CbGeAlD
Nilotinib—CSF1R—lymphoid tissue—ocular cancer	0.00148	0.0101	CbGeAlD
Nilotinib—KIT—lymphoid tissue—ocular cancer	0.00134	0.00915	CbGeAlD
Nilotinib—PDGFRB—lymphoid tissue—ocular cancer	0.00131	0.00894	CbGeAlD
Nilotinib—CA1—lymphoid tissue—ocular cancer	0.00123	0.00837	CbGeAlD
Nilotinib—ABL1—lymphoid tissue—ocular cancer	0.00117	0.00797	CbGeAlD
Nilotinib—CA2—eye—ocular cancer	0.00113	0.0077	CbGeAlD
Nilotinib—CA2—retina—ocular cancer	0.00112	0.00763	CbGeAlD
Nilotinib—CA2—epithelium—ocular cancer	0.00103	0.00704	CbGeAlD
Nilotinib—CA2—lymphoid tissue—ocular cancer	0.000797	0.00542	CbGeAlD
Nilotinib—CYP2B6—lymphoid tissue—ocular cancer	0.000681	0.00463	CbGeAlD
Nilotinib—ABCB1—retina—ocular cancer	0.000512	0.00348	CbGeAlD
Nilotinib—ABCB1—epithelium—ocular cancer	0.000473	0.00322	CbGeAlD
Nilotinib—ABCB1—lymphoid tissue—ocular cancer	0.000364	0.00248	CbGeAlD
Nilotinib—KIT—Innate Immune System—AKT1—ocular cancer	2.19e-05	4.06e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—MDM2—ocular cancer	2.18e-05	4.05e-05	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—HRAS—ocular cancer	2.18e-05	4.04e-05	CbGpPWpGaD
Nilotinib—CA7—Metabolism—AKT1—ocular cancer	2.16e-05	4.01e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—CDKN1B—ocular cancer	2.16e-05	4.01e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—EP300—ocular cancer	2.14e-05	3.97e-05	CbGpPWpGaD
Nilotinib—CA9—Metabolism—EP300—ocular cancer	2.14e-05	3.97e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—HRAS—ocular cancer	2.11e-05	3.92e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—EP300—ocular cancer	2.11e-05	3.91e-05	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—AKT1—ocular cancer	2.1e-05	3.9e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—CDKN1B—ocular cancer	2.1e-05	3.89e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CDKN2B—ocular cancer	2.1e-05	3.89e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CDKN1A—ocular cancer	2.1e-05	3.89e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—MDM2—ocular cancer	2.08e-05	3.86e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—AKT1—ocular cancer	2.07e-05	3.84e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—MDM2—ocular cancer	2.07e-05	3.84e-05	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—HRAS—ocular cancer	2.07e-05	3.84e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—AKT1—ocular cancer	2.07e-05	3.84e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—CCND1—ocular cancer	2.06e-05	3.82e-05	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—HRAS—ocular cancer	2.06e-05	3.82e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—AKT1—ocular cancer	2.06e-05	3.82e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—CDKN1B—ocular cancer	2.05e-05	3.81e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CDKN1B—ocular cancer	2.05e-05	3.8e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—HRAS—ocular cancer	2.05e-05	3.8e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—CDKN1A—ocular cancer	2.04e-05	3.79e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—HRAS—ocular cancer	2.03e-05	3.76e-05	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—AKT1—ocular cancer	2.03e-05	3.76e-05	CbGpPWpGaD
Nilotinib—MAPK11—Gene Expression—MYC—ocular cancer	2.02e-05	3.76e-05	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—AKT1—ocular cancer	2.02e-05	3.74e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—HRAS—ocular cancer	2.01e-05	3.72e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—HRAS—ocular cancer	2.01e-05	3.72e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—GNA11—ocular cancer	2.01e-05	3.72e-05	CbGpPWpGaD
Nilotinib—CA12—Metabolism—AKT1—ocular cancer	2e-05	3.72e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—CDKN1B—ocular cancer	2e-05	3.72e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—HRAS—ocular cancer	2e-05	3.71e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—EP300—ocular cancer	1.99e-05	3.7e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CDKN1B—ocular cancer	1.99e-05	3.7e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—CDKN1A—ocular cancer	1.99e-05	3.7e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—AKT1—ocular cancer	1.99e-05	3.69e-05	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—HRAS—ocular cancer	1.99e-05	3.68e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—TP53—ocular cancer	1.97e-05	3.65e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—HRAS—ocular cancer	1.96e-05	3.64e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—AKT1—ocular cancer	1.96e-05	3.64e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—CCND1—ocular cancer	1.96e-05	3.63e-05	CbGpPWpGaD
Nilotinib—HCK—Immune System—AKT1—ocular cancer	1.96e-05	3.63e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—EP300—ocular cancer	1.95e-05	3.61e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—CDKN1A—ocular cancer	1.94e-05	3.59e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—E2F1—ocular cancer	1.92e-05	3.57e-05	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—AKT1—ocular cancer	1.92e-05	3.57e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CDKN1B—ocular cancer	1.9e-05	3.52e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ocular cancer	1.9e-05	3.52e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—EP300—ocular cancer	1.9e-05	3.52e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—CDKN1A—ocular cancer	1.89e-05	3.52e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—CDKN1B—ocular cancer	1.89e-05	3.51e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CDKN1A—ocular cancer	1.89e-05	3.5e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MDM2—ocular cancer	1.88e-05	3.5e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—HRAS—ocular cancer	1.88e-05	3.49e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MDM2—ocular cancer	1.87e-05	3.46e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—GNAQ—ocular cancer	1.87e-05	3.46e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—AKT1—ocular cancer	1.86e-05	3.46e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—MYC—ocular cancer	1.86e-05	3.46e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—TGFB1—ocular cancer	1.86e-05	3.45e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—CDKN1A—ocular cancer	1.85e-05	3.43e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—EP300—ocular cancer	1.84e-05	3.42e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CDKN1A—ocular cancer	1.84e-05	3.41e-05	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—AKT1—ocular cancer	1.83e-05	3.39e-05	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—AKT1—ocular cancer	1.82e-05	3.37e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—AKT1—ocular cancer	1.81e-05	3.35e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—EP300—ocular cancer	1.8e-05	3.35e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—MDM2—ocular cancer	1.8e-05	3.34e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—EP300—ocular cancer	1.8e-05	3.33e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—AKT1—ocular cancer	1.79e-05	3.32e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—AKT1—ocular cancer	1.77e-05	3.29e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—AKT1—ocular cancer	1.77e-05	3.29e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—AKT1—ocular cancer	1.77e-05	3.28e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—EP300—ocular cancer	1.76e-05	3.26e-05	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—AKT1—ocular cancer	1.75e-05	3.25e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CDKN1A—ocular cancer	1.75e-05	3.25e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—EP300—ocular cancer	1.75e-05	3.25e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GNA11—ocular cancer	1.75e-05	3.24e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—CDKN1A—ocular cancer	1.74e-05	3.24e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—AKT1—ocular cancer	1.73e-05	3.21e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CDKN1B—ocular cancer	1.72e-05	3.19e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CDKN1B—ocular cancer	1.7e-05	3.16e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MDM2—ocular cancer	1.7e-05	3.15e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—MYC—ocular cancer	1.7e-05	3.15e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—HRAS—ocular cancer	1.69e-05	3.14e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—TGFB1—ocular cancer	1.69e-05	3.14e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—EP300—ocular cancer	1.67e-05	3.09e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—AKT1—ocular cancer	1.66e-05	3.08e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—MDM2—ocular cancer	1.66e-05	3.08e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—EP300—ocular cancer	1.66e-05	3.08e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—MYC—ocular cancer	1.65e-05	3.07e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TGFB1—ocular cancer	1.65e-05	3.06e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GNA11—ocular cancer	1.65e-05	3.06e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—CDKN1B—ocular cancer	1.64e-05	3.05e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CCND1—ocular cancer	1.64e-05	3.05e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GNA11—ocular cancer	1.63e-05	3.03e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—HRAS—ocular cancer	1.63e-05	3.02e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CCND1—ocular cancer	1.63e-05	3.02e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GNAQ—ocular cancer	1.63e-05	3.02e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MDM2—ocular cancer	1.61e-05	2.98e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—MYC—ocular cancer	1.6e-05	2.98e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—TGFB1—ocular cancer	1.6e-05	2.97e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—HRAS—ocular cancer	1.6e-05	2.97e-05	CbGpPWpGaD
Nilotinib—CA4—Metabolism—AKT1—ocular cancer	1.6e-05	2.97e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CDKN1A—ocular cancer	1.59e-05	2.95e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CDKN1A—ocular cancer	1.57e-05	2.92e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—MYC—ocular cancer	1.57e-05	2.92e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TGFB1—ocular cancer	1.57e-05	2.91e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CDKN1B—ocular cancer	1.55e-05	2.88e-05	CbGpPWpGaD
Nilotinib—CA2—Metabolism—AKT1—ocular cancer	1.53e-05	2.84e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GNAQ—ocular cancer	1.53e-05	2.84e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GNAQ—ocular cancer	1.52e-05	2.82e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—CDKN1B—ocular cancer	1.52e-05	2.81e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—CDKN1A—ocular cancer	1.52e-05	2.81e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—EP300—ocular cancer	1.51e-05	2.8e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—ocular cancer	1.51e-05	2.79e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—EP300—ocular cancer	1.5e-05	2.78e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—AKT1—ocular cancer	1.5e-05	2.78e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CCND1—ocular cancer	1.48e-05	2.75e-05	CbGpPWpGaD
Nilotinib—CA1—Metabolism—AKT1—ocular cancer	1.47e-05	2.73e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CDKN1B—ocular cancer	1.47e-05	2.72e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—HRAS—ocular cancer	1.46e-05	2.71e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MDM2—ocular cancer	1.45e-05	2.69e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—MYC—ocular cancer	1.45e-05	2.68e-05	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—MYC—ocular cancer	1.45e-05	2.68e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—TGFB1—ocular cancer	1.44e-05	2.68e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—HRAS—ocular cancer	1.44e-05	2.68e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—EP300—ocular cancer	1.44e-05	2.68e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—AKT1—ocular cancer	1.44e-05	2.67e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CDKN1A—ocular cancer	1.43e-05	2.66e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MDM2—ocular cancer	1.42e-05	2.63e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—AKT1—ocular cancer	1.41e-05	2.62e-05	CbGpPWpGaD
Nilotinib—MAPK11—Gene Expression—AKT1—ocular cancer	1.4e-05	2.61e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CCND1—ocular cancer	1.4e-05	2.6e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—CDKN1A—ocular cancer	1.4e-05	2.6e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—HRAS—ocular cancer	1.37e-05	2.53e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—EP300—ocular cancer	1.36e-05	2.53e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TP53—ocular cancer	1.36e-05	2.52e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CDKN1A—ocular cancer	1.36e-05	2.51e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MDM2—ocular cancer	1.34e-05	2.5e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—HRAS—ocular cancer	1.33e-05	2.47e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—EP300—ocular cancer	1.33e-05	2.47e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CDKN1B—ocular cancer	1.32e-05	2.45e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MYC—ocular cancer	1.32e-05	2.44e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TGFB1—ocular cancer	1.31e-05	2.44e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MYC—ocular cancer	1.3e-05	2.42e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TGFB1—ocular cancer	1.3e-05	2.41e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—HRAS—ocular cancer	1.3e-05	2.41e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CDKN1B—ocular cancer	1.3e-05	2.4e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—AKT1—ocular cancer	1.29e-05	2.4e-05	CbGpPWpGaD
Nilotinib—CA9—Metabolism—AKT1—ocular cancer	1.29e-05	2.4e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TP53—ocular cancer	1.29e-05	2.39e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—EP300—ocular cancer	1.29e-05	2.39e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—AKT1—ocular cancer	1.27e-05	2.36e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—EP300—ocular cancer	1.27e-05	2.36e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CCND1—ocular cancer	1.26e-05	2.34e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—HRAS—ocular cancer	1.26e-05	2.34e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CCND1—ocular cancer	1.24e-05	2.29e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—HRAS—ocular cancer	1.23e-05	2.29e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—HRAS—ocular cancer	1.23e-05	2.28e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CDKN1B—ocular cancer	1.23e-05	2.28e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—ocular cancer	1.23e-05	2.27e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CDKN1A—ocular cancer	1.22e-05	2.27e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—AKT1—ocular cancer	1.21e-05	2.24e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—HRAS—ocular cancer	1.2e-05	2.23e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—HRAS—ocular cancer	1.2e-05	2.22e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CDKN1A—ocular cancer	1.2e-05	2.22e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MYC—ocular cancer	1.19e-05	2.2e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TGFB1—ocular cancer	1.18e-05	2.2e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—AKT1—ocular cancer	1.18e-05	2.18e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CCND1—ocular cancer	1.17e-05	2.17e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MDM2—ocular cancer	1.16e-05	2.16e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—EP300—ocular cancer	1.16e-05	2.16e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—MYC—ocular cancer	1.16e-05	2.15e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—TGFB1—ocular cancer	1.16e-05	2.15e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—AKT1—ocular cancer	1.15e-05	2.13e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—HRAS—ocular cancer	1.14e-05	2.12e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—EP300—ocular cancer	1.14e-05	2.11e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—HRAS—ocular cancer	1.14e-05	2.11e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CDKN1A—ocular cancer	1.13e-05	2.1e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MYC—ocular cancer	1.12e-05	2.09e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TGFB1—ocular cancer	1.12e-05	2.08e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—AKT1—ocular cancer	1.11e-05	2.06e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—AKT1—ocular cancer	1.09e-05	2.02e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—AKT1—ocular cancer	1.09e-05	2.01e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TP53—ocular cancer	1.08e-05	2.01e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—EP300—ocular cancer	1.08e-05	2e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—EP300—ocular cancer	1.08e-05	2e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GNA11—ocular cancer	1.08e-05	2e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TP53—ocular cancer	1.07e-05	1.99e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—AKT1—ocular cancer	1.06e-05	1.97e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CDKN1B—ocular cancer	1.06e-05	1.97e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—AKT1—ocular cancer	1.06e-05	1.96e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—HRAS—ocular cancer	1.03e-05	1.92e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—HRAS—ocular cancer	1.02e-05	1.9e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCND1—ocular cancer	1.01e-05	1.88e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MYC—ocular cancer	1.01e-05	1.88e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TGFB1—ocular cancer	1.01e-05	1.87e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—AKT1—ocular cancer	1.01e-05	1.87e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—AKT1—ocular cancer	1e-05	1.86e-05	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—AKT1—ocular cancer	1e-05	1.86e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GNAQ—ocular cancer	1e-05	1.86e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MYC—ocular cancer	9.91e-06	1.84e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TGFB1—ocular cancer	9.89e-06	1.83e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—HRAS—ocular cancer	9.87e-06	1.83e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CDKN1A—ocular cancer	9.8e-06	1.82e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TP53—ocular cancer	9.75e-06	1.81e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MYC—ocular cancer	9.4e-06	1.74e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TGFB1—ocular cancer	9.37e-06	1.74e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—HRAS—ocular cancer	9.32e-06	1.73e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—EP300—ocular cancer	9.32e-06	1.73e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TP53—ocular cancer	9.23e-06	1.71e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—AKT1—ocular cancer	9.13e-06	1.69e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—HRAS—ocular cancer	9.11e-06	1.69e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—AKT1—ocular cancer	9.04e-06	1.68e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—HRAS—ocular cancer	8.83e-06	1.64e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—AKT1—ocular cancer	8.71e-06	1.62e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TP53—ocular cancer	8.31e-06	1.54e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—AKT1—ocular cancer	8.23e-06	1.53e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TP53—ocular cancer	8.14e-06	1.51e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MYC—ocular cancer	8.12e-06	1.51e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TGFB1—ocular cancer	8.1e-06	1.5e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—AKT1—ocular cancer	8.05e-06	1.49e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—HRAS—ocular cancer	7.95e-06	1.48e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—EP300—ocular cancer	7.92e-06	1.47e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—AKT1—ocular cancer	7.79e-06	1.45e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—HRAS—ocular cancer	7.78e-06	1.44e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TP53—ocular cancer	7.72e-06	1.43e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—AKT1—ocular cancer	7.69e-06	1.43e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—HRAS—ocular cancer	7.38e-06	1.37e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—AKT1—ocular cancer	7.02e-06	1.3e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—AKT1—ocular cancer	6.87e-06	1.28e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—EP300—ocular cancer	6.7e-06	1.24e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TP53—ocular cancer	6.67e-06	1.24e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—AKT1—ocular cancer	6.53e-06	1.21e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—AKT1—ocular cancer	6.52e-06	1.21e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—HRAS—ocular cancer	6.38e-06	1.18e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—EP300—ocular cancer	5.84e-06	1.08e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—AKT1—ocular cancer	5.63e-06	1.05e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—EP300—ocular cancer	5.5e-06	1.02e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—EP300—ocular cancer	5.46e-06	1.01e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—AKT1—ocular cancer	4.78e-06	8.88e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—AKT1—ocular cancer	4.05e-06	7.52e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—EP300—ocular cancer	3.6e-06	6.68e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—AKT1—ocular cancer	3.53e-06	6.55e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—AKT1—ocular cancer	3.33e-06	6.17e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—AKT1—ocular cancer	3.3e-06	6.12e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—AKT1—ocular cancer	2.17e-06	4.03e-06	CbGpPWpGaD
